The problem with analysis techniques like billing errors bands is that they on,y work in isolation. Meaning, they don't consider things like financial restructuring, released news on clinical trials, anticipated results etc. they only work for stocks like GE etc.
Yeah, I'd go with that but can't short this, the upside is way too big.
But the Doctor's can't prescribe it because the SRPT management team has angered the FDA and nothing will get done now.
Yeah, it was a bargain at $50, if you bought more at a big discount at $40 you were happy, at $30 you were estatic because you could buy even more, then at $20 you couldn't believe your luck. At $15 you must be thrilled at the loss of 70%.
Like on an airplane headed straight down at Mach 4. It's too late to pull up.
... because that is your only answer? Sell and run away - instead of fix it by replacing management? You really are a passive little shareholder aren't you. Weak management's best friend. You've never started, built, and owned a company have you? Didn't think so. I've done several. The company won't get there at this rate ...
... and if we don't change the path we are on, we will end up where we are headed ...
Probably because this stock has plunged from $50 to $15. A loss of 70%.
I'll say it again. A loss of 70%.
And remember this: $0 sales if they can't even get the stupid NDA filed. Delays are now measuring in YEARS.
I'm not against the company or drug, I want it to get passed by the FDA but I do recognize the severe limitations of this executive management team. SRPT needs new management and won't get there with this team. Shareholders need to take action.
Let's see now. They are up to a grand total of ONE patient so far, so just zooming right along ...
It all depends on what data they release/announce. Could be a very good week.
Unfortunately it was precisely that, just a form letter. Still, I have to hope that every letter to the Senator helps.
So, in the same light that the other gentleman posted, here is the response I got from my Senator:
Thank you for contacting me about U.S. Food and Drug Administration (FDA) reform. In order to best represent you as your United States Senator, it is vital that I hear your views on this and other important matters.
I share your concerns about the need to reform the FDA. The Government Accountability Office (GAO), Congress' investigative arm, reported that the FDA's inability to oversee medical product and food safety would be added to its list of "high risk" government programs and practices. Reports like these are troubling and require us to take action. As we discuss FDA reform, we need to be honest about what works and what does not. This means establishing better, more robust results-oriented performance measures, aligning activities and resources to meet strategic goals, and enhancing the use of performance information. We must implement policies that adequately prepare the FDA to keep pace with changing demands.
Thank you again for contacting me. I will keep you thoughts in mind. Please continue to be in touch with your opinions and concerns as we move forward in the 113th Congress. For further information or to sign up for my newsletter please visit my website at: xxx.senate.gov
I am well aware of the big picture, and that is the SRPT executive team must be replaced. They can't get the job done.
Think about it. If the pilot is blind, it doesn't matter how good the planes engines are.
You are kidding yourself. I seriously think you mean well, but the idea is naive. The investing shorelines are littered with the wreckage of many companies that didn't have the management team to get the job done.
It is a noble idea that a righteous few can overcome a great evil; but not realistic. Especially when the righteous few are shareholders and none in the management ranks of the company.
Here is the link:
Actually it was the re-placement of some notes that moved them from 2019 to 2021. Sold some notes at 2021 and used the money to pay off the 2019 notes. So it was a restructure of financing.
You really had your trading influenced by the Yahoo anonymous message boards?
Is this just a run up or some material event that we (the average investor) doesn't know about? I like the move up, but always curious about major moves on big volume with no news to attribute it to.
Any others who got burned by SRPT as I did and want to look into another stock, check ISIS as it is up another big leg today. Careful not to buy at the peak, but could help heal your portfolio (and if you just want to buy some time in hopes SRPT comes back, then that works too).
With regard to RGLS, hard to say if it will continue up or if it has peaked, so much more cautious on that one.
CLDX should still have room to run.
Same with INCY and INSM. INCY is the better, but both round out the biotech group well.